271 related articles for article (PubMed ID: 25853305)
1. Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.
Ogata A; Morita T; Yoshida Y; Tanaka T
Ther Deliv; 2015 Mar; 6(3):283-95. PubMed ID: 25853305
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
3. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
Ogata A; Kato Y; Higa S; Maeda K
Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
Nakashima Y; Kondo M; Miyahara H; Iwamoto Y
Drug Des Devel Ther; 2014; 8():913-9. PubMed ID: 25045250
[TBL] [Abstract][Full Text] [Related]
7. Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
Ogata A; Atsumi T; Fukuda T; Hirabayashi Y; Inaba M; Ishiguro N; Kai M; Kawabata D; Kida D; Kohsaka H; Matsumura R; Minota S; Mukai M; Sumida T; Takasugi K; Tamaki S; Takeuchi T; Ueda A; Yamamoto K; Yamanaka H; Yoshifuji H; Nomura A;
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1354-62. PubMed ID: 25832859
[TBL] [Abstract][Full Text] [Related]
8. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
[TBL] [Abstract][Full Text] [Related]
10. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice.
Ahn SM; Oh JS; Heo HM; Hong S; Lee CK; Yoo B; Kim YG
J Korean Med Sci; 2022 May; 37(17):e138. PubMed ID: 35502504
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
Ogata A; Tanimura K; Sugimoto T; Inoue H; Urata Y; Matsubara T; Kondo M; Ueki Y; Iwahashi M; Tohma S; Ohta S; Saeki Y; Tanaka T;
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):344-54. PubMed ID: 23983039
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
16. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
[No Abstract] [Full Text] [Related]
18. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
20. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]